MUTYH is a potential prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma

被引:3
|
作者
Yang, Fan [1 ,2 ,3 ]
Lian, Qinghai [4 ]
Ni, Beibei [4 ]
Qiu, Xiusheng [4 ]
He, Yizhan [1 ]
Zou, Xiaoguang [2 ]
He, Fangping [5 ]
Chen, Wenjie [1 ,4 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Biotherapy Ctr, Guangzhou, Guangdong, Peoples R China
[2] First Peoples Hosp Kashi, Dept Infect Dis, Kashi, Xinjiang, Peoples R China
[3] Xinjiang Med Univ, Urumqi, Xinjiang, Peoples R China
[4] Sun Yat Sen Univ, Ailiated Hosp 3, Cell Gene Therapy Translat Med Res Ctr, Guangzhou, Guangdong, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Hepatobiliary & Pancreat Surg, Shenzhen, Guangdong, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
MUTYH; Hepatocellular carcinoma (HCC); Bioinformatics; Prognostic biomarker; Immune infiltrates; DNA-REPLICATION; CANCER; SURVEILLANCE; CHECKPOINTS; HOMOLOG;
D O I
10.1016/j.livres.2022.12.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. The development of biomarkers for early detection and monitoring of HCC has not shown significant prog-ress. Meanwhile, the second adenomatous polyposis-related gene, MUTYH, which encodes a DNA gly-cosylase, has been observed in its contribution to oxidative DNA damage repair. Abnormal expression of MUTYH can reduce cell survival rate. Therefore, this study investigated the usefulness of MUTYH in diagnosing and prognosis HCC.Materials and methods: Using The Cancer Genome Atlas (TCGA) data, we analyzed the prognostic value of MUTYH in HCC. We used logistic regression, Wilcoxon signed-rank test, and Kruskal-Wallis test to examine MUTYH expression concerning clinical-pathologic characteristics. Univariate and multivariate Cox regression methods and Kaplan-Meier analysis were applied to determine the related prognostic factors of HCC. The enrichment analysis (GSEA) was used to determine the critical pathways associated with MUTYH. The single-sample gene set enrichment analysis (ssGSEA) was conducted to examine the correlation between MUTYH expression and cancer immune infiltration.Results: The higher expression of MUTYH in HCC patients was associated with a poorer overall survival rate and a shorter disease-specific survival rate. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that all differentially expressed genes (DEGs) between the high and low expression levels of MUTYH significantly enriched in the trace ligand-receptor interaction, cell cycle, oocyte meiosis, gap junction, and DNA replication. Group analysis revealed the signals of their open access. The neuron system, M phase, DNA repair, Rho GTPase effector, and cell cycle checkpoints were significantly enriched. ssGSEA showed a positive correlation between MUTYH expression and the infiltration levels of Th2 cells, NK cells, and T helper cells. Moreover, a negative correlation was found between MUTYH expression and the infiltration levels of dendritic cells (DCs) and cytotoxic cells.Conclusions: MUTYH expression levels were positively correlated with immune checkpoint gene expression levels in HCC tissues. The expression level of MUTYH was related to the prognosis of HCC and the immune infiltration of HCC.& COPY; 2022 The Third Affiliated Hospital of Sun Yat-sen University. Publishing services by Elsevier B. V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:258 / 268
页数:11
相关论文
共 50 条
  • [21] PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma
    Ni, Wenpeng
    Yi, Lijuan
    Dong, Xiaoru
    Cao, Mengjie
    Zheng, Jinjuan
    Wei, Qingling
    Yuan, Chunlei
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [22] Prognostic biomarker SMARCC1 and its association with immune infiltrates in hepatocellular carcinoma
    Cai, Xiaopeng
    Zhou, Jiaming
    Deng, Jingwen
    Chen, Zhi
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [23] LARS1 is a Prognostic Biomarker and Exhibits a Correlation with Immune Infiltrates in Hepatocellular Carcinoma
    Fan, Longfei
    Qin, Zhongqiang
    Wu, Di
    Yang, Yunchuan
    Zhang, Yigang
    Xie, Bo
    Qian, Jingyu
    Wei, Jianzhu
    Wang, Zhaoying
    Yang, Peipei
    Qian, Zhen
    Yuan, Mu
    Zhu, Ziyi
    Tan, Yulin
    Tan, Yi
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17 : 2203 - 2221
  • [24] Poor Prognostic Biomarker KIAA1522 Is Associated with Immune Infiltrates in Hepatocellular Carcinoma
    Shi, Yongjie
    Xiao, Qiwen
    Huang, Sicong
    Pan, Qimou
    Jia, Hongyun
    Zhou, Qiang
    Wei, Jie
    Kang, Jiale
    Li, Zhe
    Hu, Yingyu
    JOURNAL OF ONCOLOGY, 2023, 2023
  • [25] Prognostic biomarker SMARCC1 and its association with immune infiltrates in hepatocellular carcinoma
    Xiaopeng Cai
    Jiaming Zhou
    Jingwen Deng
    Zhi Chen
    Cancer Cell International, 21
  • [26] TCN1 is a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma
    Haining Li
    Liping Guo
    Zhigang Cai
    World Journal of Surgical Oncology, 20
  • [27] EDIL3 is a potential prognostic biomarker that correlates with immune infiltrates in gastric cancer
    Ke, Bin
    Liang, Zheng-Kai
    Li, Bin
    Wang, Xue-Jun
    Liu, Ning
    Liang, Han
    Zhang, Ru-Peng
    PEERJ, 2023, 11
  • [28] TCN1 is a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma
    Li, Haining
    Guo, Liping
    Cai, Zhigang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [29] ASF1B, as an Independent Prognostic Biomarker, Correlates withImmune Infiltrates in Hepatocellular Carcinoma
    Li, Renzhi
    Cui, Xiaohan
    Sun, Weijun
    Yang, Zhen
    Shen, Xingyuan
    Zhu, Chunfu
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2023, 26 (07) : 1311 - 1323
  • [30] GPI Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Lung Adenocarcinoma
    Han, Jiahui
    Deng, Xinzhou
    Sun, Renhuang
    Luo, Ming
    Liang, Meng
    Gu, Bing
    Zhang, Te
    Peng, Zhen
    Lu, Ying
    Tian, Chao
    Yan, Yutao
    Luo, Zhiguo
    FRONTIERS IN ONCOLOGY, 2021, 11